A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 29 Apr 2022
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary) ; Vedolizumab
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms LUCENT-ACT
- Sponsors Eli Lilly and Company
- 10 Jun 2021 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
- 08 Jun 2021 This trial has been completed in France (End Date: 16 Apr 2021), according to European Clinical Trials Database record.
- 07 May 2021 This trial has been discontinued in Lithuania and Latvia (End Date: 16 Apr 2021), according to European Clinical Trials Database record.